Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Biomark Diagnostics's share price for the quarter that ended in Dec. 2023 was $0.18. Biomark Diagnostics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 90.89 Mil. Therefore, Biomark Diagnostics's market cap for the quarter that ended in Dec. 2023 was $16.36 Mil.
Biomark Diagnostics's quarterly market cap
declined
from Jun. 2023 ($19.91 Mil) to Sep. 2023 ($17.49 Mil) and
declined
from Sep. 2023 ($17.49 Mil) to Dec. 2023 ($16.36 Mil).
Biomark Diagnostics's annual market cap
declined
from Mar. 2021 ($25.30 Mil) to Mar. 2022 ($13.65 Mil) and
declined
from Mar. 2022 ($13.65 Mil) to Mar. 2023 ($11.87 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Biomark Diagnostics's Enterprise Value for Today is $20.78 Mil.
Biomark Diagnostics Market Cap Historical Data
The historical data trend for Biomark Diagnostics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Biomark Diagnostics's Market Cap
For the Diagnostics & Research subindustry, Biomark Diagnostics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomark Diagnostics's Market Cap Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's Market Cap distribution charts can be found below:
* The bar in red indicates where Biomark Diagnostics's Market Cap falls into.
Biomark Diagnostics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Biomark Diagnostics's Market Cap for the fiscal year that ended in Mar. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomark Diagnostics (OTCPK:BMKDF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Biomark Diagnostics Market Cap Related Terms
Thank you for viewing the detailed overview of Biomark Diagnostics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Biomark Diagnostics (Biomark Diagnostics) Business Description
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BMKDF has been successfully added to your 